Status:
UNKNOWN
Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)
Lead Sponsor:
Charite University, Berlin, Germany
Collaborating Sponsors:
ribosepharm GmbH
Conditions:
Recurrent Small Cell Lung Cancer
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Determination of response rate Assessment of toxicity and determination of "time to progression"
Detailed Description
Phase II Study to determine the efficacy of Bendamustin(Ribomustin) in patients with recurrent small cell bronchial carcinoma after cytostatic polychemotherapy
Eligibility Criteria
Inclusion
- Patients with histological proven, curative non treatable small lung cell carcinoma
- Recurrence \>8 weeks, \> 1 year after 1st line treatment with platin- and etoposide polychemotherapy, without brain metastases
Exclusion
- Brain metastases
- WHO-PS 3 - 4
Key Trial Info
Start Date :
February 1 2001
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00168922
Start Date
February 1 2001
End Date
December 1 2006
Last Update
April 27 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hematology & Oncology Charité CBF Berlin, Germany
Berlin, State of Berlin, Germany, 12203